Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S25, October 2017

Long Term Use of Tolvaptan Reduced Re-admission Due to Cardiac Events in Over 85-year Old Patients

      Introduction: We reported the mortality and morbidity of patients, over 85-year old, with cardiac diseases in our institution. Long term use of Tolvaptan improved the rate of readmission. Methods and Results: From October/2016 to May/2017, forty-three patients with cardiac diseases admitted in our institution. Thirty-one patients discharged and Tolvaptan (3.75 mg or 7.5 mg) was continuously used for 22 among 31 patients after discharge. First re-admission was observed in 13 patients. By Kaplan-Meier method, the mortality and first re-admission rate due to all causes were 70%, but competitive risk with cardiac mortality was 15%, non-cardiac mortality was 7.5%, cardiac re-admission was 13% and non-cardiac re-admission was 33%. Conclusion: Cardiac events induced to the high rate of mortality, but long term use of Tolvaptan reduced re-admission with cardiac events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect